Home > Urology > EAU 2019 > Bladder Cancer > FGFR3 gene mutation: Favourable prognostic impact in bladder cancer

FGFR3 gene mutation: Favourable prognostic impact in bladder cancer

Presented By
Dr Laura Mertens, VU Amsterdam Medical Center, the Netherlands
Conference
EAU 2019
The fibroblast growth factor receptor (FGFR) pathway is very important in bladder cancer. Dr Laura Mertens (VU Amsterdam Medical Center, the Netherlands) shared her data analysing activating FGFR3 mutations vs FGFR3 protein overexpression in bladder tumours and their relation to clinic-pathological parameters and prognosis in a multicentre, multi-laboratory setting. She concluded that FGFR3 mutation has favourable prognostic impact regardless of FGFR3 protein expression level. FGFR3 activating mutations are known to be associated with favourable prognosis in bladder cancer [1], yet little is known about whether immunohistochemical detection of overexpression of FGFR3 is a relevant prognostic tool. Because the FGFR3 receptor is an actionable target and there are drugs in the pipeline, Dr Mertens took 1,000 cN0M0 (chemo-naïve) bladder cancer patients who underwent radical cystectomy (in 9 hospitals) and concomitantly screened them ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on